MX9707949A - Peptido-2 semejante al glucagon y su uso terapeutico. - Google Patents
Peptido-2 semejante al glucagon y su uso terapeutico.Info
- Publication number
- MX9707949A MX9707949A MX9707949A MX9707949A MX9707949A MX 9707949 A MX9707949 A MX 9707949A MX 9707949 A MX9707949 A MX 9707949A MX 9707949 A MX9707949 A MX 9707949A MX 9707949 A MX9707949 A MX 9707949A
- Authority
- MX
- Mexico
- Prior art keywords
- glucagon
- peptide
- therapeutic use
- bowel
- analogs
- Prior art date
Links
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008467 tissue growth Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
Abstract
Péptido-2 semejante al glucagon, un producto de expresion del gen glucagon, y análogos de péptido-2 semejante al glucagon, han sido identificados como factores de crecimiento de tejido gastrointestinal. Se describen sus efectos en el crecimiento del intestino delgado e islotes pancreáticos. Se describe su formulacion como un farmacéutico y su uso terapéutico en el tratamiento de desordenes del intestino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/422,540 US5990077A (en) | 1995-04-14 | 1995-04-14 | Glucagon-like peptide-2 and its therapeutic use |
| US08422540 | 1995-04-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9707949A true MX9707949A (es) | 1998-06-30 |
| MXPA97007949A MXPA97007949A (es) | 1998-10-30 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| ES2334864T5 (es) | 2013-04-08 |
| DK0830377T3 (da) | 2010-03-01 |
| EP2277909A1 (en) | 2011-01-26 |
| CN100374461C (zh) | 2008-03-12 |
| CA2218225C (en) | 2014-09-23 |
| AU720493B2 (en) | 2000-06-01 |
| JP4496183B2 (ja) | 2010-07-07 |
| EP2277530A1 (en) | 2011-01-26 |
| AU5265896A (en) | 1996-10-30 |
| CA2218225A1 (en) | 1996-10-17 |
| JP2006342172A (ja) | 2006-12-21 |
| PT830377E (pt) | 2010-01-19 |
| DK0830377T4 (da) | 2013-03-11 |
| JP2010159259A (ja) | 2010-07-22 |
| JPH11505521A (ja) | 1999-05-21 |
| CN1188485A (zh) | 1998-07-22 |
| EP1988100B1 (en) | 2015-03-04 |
| EP0830377A1 (en) | 1998-03-25 |
| WO1996032414A1 (en) | 1996-10-17 |
| EP0830377B2 (en) | 2012-12-12 |
| DE69638057D1 (de) | 2009-11-26 |
| US5990077A (en) | 1999-11-23 |
| CN101254300A (zh) | 2008-09-03 |
| EP1988100A1 (en) | 2008-11-05 |
| EP0830377B1 (en) | 2009-10-14 |
| ATE445641T1 (de) | 2009-10-15 |
| ES2334864T3 (es) | 2010-03-16 |
| CY2615B2 (en) | 2012-01-25 |
| JP5281594B2 (ja) | 2013-09-04 |
| CN101254300B (zh) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2615B2 (en) | Glucagon-like peptide-2 and its therapeutic use | |
| EP2218734A3 (en) | Glucagon-like peptide-2 analogs | |
| PT703786E (pt) | Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida | |
| NO962088D0 (no) | Preparat for in vivo-produksjon av terapeutiske produkter | |
| IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
| ZA975866B (en) | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases. | |
| MY128809A (en) | Pharmaceutical formulation of omeprazole | |
| ATE338771T1 (de) | Antagonisten des intestinotrophen glp-2 peptides | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| NO953278D0 (no) | Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette | |
| ATE205086T1 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
| GB9408775D0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration | |
| AU7239996A (en) | Inhibition of tumor necrosis factor alpha | |
| WO1999022722A3 (en) | Use of macrolides for the treatment of cancer and macular degeneration | |
| DE69821929D1 (de) | Pharmazeutische zusammensetzung zur behandlung von parkinsonkrankheit oder depression | |
| BG105275A (en) | Tan-1057 derivatives | |
| AU3862997A (en) | Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof | |
| AU1898792A (en) | Treatment or therapeutic booth for energetic, cosmetic and medical purposes | |
| DK0703781T3 (da) | Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom | |
| ATE147988T1 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
| PL365913A1 (en) | Novel therapeutic use of a thienylcyclohexylamine derivative | |
| UA32580C2 (uk) | Засіб для лікування паралітичної непрохідності кишечнику | |
| MX9605327A (es) | Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis. | |
| IT1254688B (it) | Composizioni farmaceutiche somministrabili per via orale a rilascio mirato contenenti acido ursodesossicolico ed acido chenodesossicolico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |